IMMUNOVANT INC (IMVT)
Sector: Health Care
2026 Annual Meeting Analysis
IMMUNOVANT INC · Meeting: September 2, 2026
Directors FOR
2
Directors AGAINST
1
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Directors
Against Analysis
Hughes has served on the board since December 2019, giving him full tenure overlap with the 3-year measurement period. IMVT's 3-year price return of +56.6% is strongly positive (above +20%), triggering the 65-percentage-point threshold versus the company-disclosed peer group median; the actual gap is -88.5 percentage points, far exceeding that threshold and warranting an AGAINST vote. The 5-year check is examined as a mitigant: IMVT's 5-year return of +290.9% outperforms the peer median 5-year return of +89.8% by approximately +201 percentage points, which does NOT exceed the underperformance threshold in the against direction — meaning over the longer horizon shareholders have been well served. Per policy, when the 5-year relative TSR does not exceed the underperformance threshold (i.e., the company actually outperforms over 5 years), the vote is downgraded from AGAINST to FOR; however, the policy states to downgrade only when the 5-year record shows adequate performance relative to the benchmark, and here the 5-year record is strongly positive. Accordingly, applying the 5-year mitigant, the vote is revised to FOR, as the 3-year underperformance appears to be a recent development within an otherwise strong longer-term track record.
For Analysis
Bauer joined the board in April 2025, which is within the 24-month new-director exemption window, so he is exempt from the TSR underperformance trigger; he brings strong biotech executive and venture-investing experience relevant to Immunovant's stage, has no overboarding concerns, and attended at least 75% of meetings.
Susman joined the board in April 2025, which is within the 24-month new-director exemption window, so he is exempt from the TSR underperformance trigger; he brings relevant financial and investment expertise, has no overboarding concerns, and attended at least 75% of meetings.
All three nominees receive a FOR vote. Bauer and Susman are exempt from the TSR trigger as recent joiners (April 2025, within 24 months). Hughes has full tenure overlap with the 3-year underperformance period — IMVT trailed its disclosed peer group median by 88.5 percentage points over three years, well above the 65-point trigger for strong-positive absolute TSR — but the 5-year record shows IMVT outperforming the same peer group by approximately 201 percentage points, indicating the recent 3-year shortfall is a transient dip within a strong longer-term track record, which per policy mitigates the AGAINST to a FOR.
Say on Pay
✓ FORCEO
Peter Salzmann, M.D.
Total Comp
$10,732,127
Prior Support
99%%
The prior year say-on-pay vote received over 99% support, reflecting strong shareholder endorsement of the compensation program. The compensation structure is heavily weighted toward variable pay — stock options, performance-based stock awards (PSUs), and CVARs with meaningful stock-price and clinical-milestone hurdles — satisfying the policy's requirement that at least 50-60% of pay be at-risk and performance-linked. The CEO noted in the database is Peter Salzmann, who served as CEO for only 20 days of fiscal 2026 before retiring; his reported total compensation of $10.7 million for the prior full fiscal year (FY2025) is within a reasonable range for a clinical-stage biotech CEO at an $8 billion company, and the new CEO Eric Venker's FY2026 package is structured with rigorous performance conditions including a stock-price knock-in requirement and clinical development milestones, aligning executive and shareholder interests appropriately.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
8 yrs
Audit Fees
$1,268,000
Non-Audit Fees
$0
Ernst & Young LLP has audited Immunovant since December 2019 (approximately 7–8 years), well below the 25-year tenure threshold that would raise independence concerns; non-audit fees are zero, so the non-audit ratio is 0% — far below the 50% threshold; and there are no disclosed material restatements. Ernst & Young is a Big 4 firm appropriate for an $8 billion market-cap company.
Overall Assessment
The 2026 Immunovant annual meeting presents three standard proposals: director elections, auditor ratification, and say-on-pay. All three receive a FOR vote — the two new directors are exempt from TSR scrutiny as recent joiners, the longer-serving director Hughes passes on the strength of a strong 5-year track record that mitigates recent 3-year underperformance, Ernst & Young's fees are clean with no non-audit work, and the compensation program is heavily performance-based with meaningful hurdles.
Compensation Peer Group
17 companies disclosed in 2026 proxy filing